Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling.
Lianlian Tian,Jun-Long Zhao,Jian-Qin Kang,Shibo Guo,Nini Zhang,Lei Shang,Ya-Long Zhang,Jian Zhang,Xun Jiang,Yan Lin +9 more
TLDR
Wang et al. as mentioned in this paper found that Astragaloside IV attenuated clinical activity of DSS-induced colitis that mimics human IBD and resulted in the phenotypic transition of macrophages from immature pro-inflammatory macrophage to mature pro-resolving macophages.Abstract:
Inflammatory bowel disease (IBD) is characterized by chronic and relapsing intestinal inflammation, which currently lacks safe and effective medicine. Some previous studies indicated that Astragaloside IV (AS-IV), a natural saponin extracted from the traditional Chinese medicine herb Ligusticum chuanxiong, alleviates the experimental colitis symptoms in vitro and in vivo. However, the mechanism of AS-IV on IBD remains unclear. Accumulating evidence suggests that M2-polarized intestinal macrophages play a pivotal role in IBD progression. Here, we found that AS-IV attenuated clinical activity of DSS-induced colitis that mimics human IBD and resulted in the phenotypic transition of macrophages from immature pro-inflammatory macrophages to mature pro-resolving macrophages. In vitro, the phenotype changes of macrophages were observed by qRT-PCR after bone marrow-derived macrophages (BMDMs) were induced to M1/M2 and incubated with AS-IV, respectively. In addition, AS-IV was effective in inhibiting pro-inflammatory macrophages and promoting the pro-resolving macrophages to ameliorate experimental colitis via the regulation of the STAT signaling pathway. Hence, we propose that AS-IV can ameliorate experimental colitis partially by modulating macrophage phenotype by remodeling the STAT signaling, which seems to have an essential function in the ability of AS-IV to alleviate the pathological progress of IBD.read more
Citations
More filters
Journal ArticleDOI
A potential therapeutic target in traditional Chinese medicine for ulcerative colitis: Macrophage polarization
Zhihua Yang,Shan-Shan Lin,Wan-Shu Feng,Yangxi Liu,Zhihui Song,Gui-Xia Pan,Yuhang Zhang,Xiangdong Dai,X. Ding,Lu Lu Chen,Yi Wang +10 more
TL;DR: Evidence has shown that traditional Chinese medicine (TCM) has positive therapeutic effects on UC by restoring the balance of M1/M2 macrophage polarization, and the potential mechanism of TCM regulating macrophages polarization in the treatment of UC is summarized.
Journal ArticleDOI
Traditional Chinese Medicine and Natural Products: Potential Approaches for Inflammatory Bowel Disease
TL;DR: This paper reviews the mechanism and research status of TCM and natural products in IBD treatment by analyzing the relevant literature to provide a scientific and theoretical basis for IBD diagnosis and treatment.
Journal ArticleDOI
Astragalus polysaccharide alleviates ulcerative colitis by regulating the balance of Tfh/Treg cells.
Youbao Zhong,Qiuping Xiao,Zeng-Ping Kang,Jia-Qi Huang,Wei Ge,Q. Wan,Hai-Yan Wang,Wen Zhou,Hai-Mei Zhao,Duan-Yong Liu +9 more
TL;DR: In this article , dextran sodium sulfate induced mice UC and Astragalus polysaccharide (APS, 200 mg/kg/day) was administered simultaneously, and APS effectively alleviated colitis in mice by improving survival rate, disease activity index (DAI), the change rate of body weight, colonic length and weight, and histopathological injury of the colon.
Journal ArticleDOI
Astragalus Mongholicus: A review of its anti-fibrosis properties
TL;DR: Wang et al. as discussed by the authors conducted a literature search to gain insight into the role of astragalus mongholicus (AM) in treating fibro-related diseases, and concluded that AM can be used to intervene in fibrosis-disease progression by regulating inflammation, oxidative stress, the immune system, and metabolism.
Journal ArticleDOI
Astragaloside Ⅳ alleviates ulcerative colitis by regulating the balance of Th17/Treg cells.
Youbao Zhong,Wenjun Liu,Yanxia Xiong,Yingmeng Li,Q. Wan,Wen Zhou,Hai-Mei Zhao,Qiuping Xiao,Duan-Yong Liu +8 more
TL;DR: Astragaloside IV (AS-Ⅳ) is a phytochemical naturally occurring in Astragalus membranaceus that has good anti-inflammatory, anti-oxidant and anti-stress properties as discussed by the authors .
References
More filters
Journal ArticleDOI
Mechanisms and consequences of Jak–STAT signaling in the immune system
TL;DR: Recent advances in Jak–STAT biology are reviewed, focusing on immune cell function, disease etiology and therapeutic intervention, as well as broader principles of gene regulation and signal-dependent TFs.
Journal ArticleDOI
Diversity, Mechanisms, and Significance of Macrophage Plasticity
TL;DR: Macrophage plasticity, an essential component of chronic inflammation, and its involvement in diverse human diseases, most notably cancer, is discussed here as a paradigm.
Journal ArticleDOI
Developmental and Functional Heterogeneity of Monocytes.
TL;DR: Emerging concepts in monocyte heterogeneity, emergency monopoiesis, and trained immunity are outlined and discussed and how these bring new perspectives to monocyte research are discussed.
Journal ArticleDOI
Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt,Jørn Brynskov,Ole Østergaard Thomsen,Lars Kristian Munck,Jan Fallingborg,Lisbet Ambrosius Christensen,Gitte Pedersen,Jens Kjeldsen,Bent Ascanius Jacobsen,Anne Sophie Oxholm,Jakob Kjellberg,Klaus Bendtzen,Mark A. Ainsworth +12 more
TL;DR: Treatment of secondary IFX failure using an algorithm based on combined IFX and IFX antibody measurements significantly reduces average treatment costs per patient compared with routine IFX dose escalation and without any apparent negative effect on clinical efficacy.
Journal ArticleDOI
Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD
TL;DR: A deeper understanding of the molecular pathways involved in the differentiation and functions of intestinal macrophages might lead to a new class of targets to promote remission in patients with IBD.